July 18, 2012 10:47 AM | 1 min read
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
In a report published Wednesday, Cantor Fitzgerald reiterated its Sell rating on Ironwood Pharmaceuticals (NASDAQ: IRWD), but lowered its price target from $10.00 to $7.00.Cantor Fitzgerald noted, “Ironwood reported a loss of ($0.38) in 2Q:12 that exceeded consensus estimates of ($0.32) due to greater-than-expected R&D and G&A spending. We are lowering our price target to incorporate assumptions of even bigger spending levels and delayed profitability until Linaclotide can attain blockbuster status in 2019. Though IRWD could be volatile ahead of the Linaclotide PDUFA, we believe that the stock is overvalued and could see a sell-off after that event once the company's key catalyst plays out.”Ironwood Pharmaceuticals closed on Tuesday at $13.25.
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.